The evolving landscape of antibody-drug conjugates in ovarian cancer: new drugs for a new era.

IF 2.2 4区医学 Q2 OBSTETRICS & GYNECOLOGY

Current Opinion in Obstetrics & Gynecology Pub Date : 2024-04-01 Epub Date: 2024-01-02 DOI:10.1097/GCO.0000000000000934

David García-Illescas, Roberta Mazzeo, Carmen García-Durán, Ana Oaknin

{"title":"The evolving landscape of antibody-drug conjugates in ovarian cancer: new drugs for a new era.","authors":"David García-Illescas, Roberta Mazzeo, Carmen García-Durán, Ana Oaknin","doi":"10.1097/GCO.0000000000000934","DOIUrl":null,"url":null,"abstract":"Purpose of review: This review addresses the emerging role of antibody-drug conjugates (ADCs) in the treatment of ovarian cancer, a field marked by a high need for more effective and targeted therapies. Given the recent advancements in ADC technology and the ongoing challenges in treating ovarian cancer, particularly in late-stage and recurrent cases, this review is both timely and relevant. It synthesizes current research findings and clinical trial data, highlighting the potential of ADCs to revolutionize ovarian cancer treatment.Recent findings: The review covers key themes including the mechanism of action of ADCs, their specificity in targeting ovarian cancer cells, recent clinical trial outcomes, advancements in ADC design for improved efficacy and reduced toxicity, and strategies to overcome drug resistance in ovarian cancer. It also addresses the heterogeneity of ovarian cancer and the implications for personalized ADC therapies.Summary: The review underscores the potential of ADCs to significantly impact clinical practice, offering a more effective and personalized treatment approach for ovarian cancer patients. The review suggests a paradigm shift in the treatment of this malignancy, emphasizing the need for further research and development in this area.","PeriodicalId":55194,"journal":{"name":"Current Opinion in Obstetrics & Gynecology","volume":" ","pages":"104-111"},"PeriodicalIF":2.2000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Obstetrics & Gynecology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/GCO.0000000000000934","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/2 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: This review addresses the emerging role of antibody-drug conjugates (ADCs) in the treatment of ovarian cancer, a field marked by a high need for more effective and targeted therapies. Given the recent advancements in ADC technology and the ongoing challenges in treating ovarian cancer, particularly in late-stage and recurrent cases, this review is both timely and relevant. It synthesizes current research findings and clinical trial data, highlighting the potential of ADCs to revolutionize ovarian cancer treatment.

Recent findings: The review covers key themes including the mechanism of action of ADCs, their specificity in targeting ovarian cancer cells, recent clinical trial outcomes, advancements in ADC design for improved efficacy and reduced toxicity, and strategies to overcome drug resistance in ovarian cancer. It also addresses the heterogeneity of ovarian cancer and the implications for personalized ADC therapies.

Summary: The review underscores the potential of ADCs to significantly impact clinical practice, offering a more effective and personalized treatment approach for ovarian cancer patients. The review suggests a paradigm shift in the treatment of this malignancy, emphasizing the need for further research and development in this area.

查看原文本刊更多论文

卵巢癌抗体药物共轭物的演变：新时代的新药物。

综述的目的：本综述探讨了抗体-药物共轭物（ADC）在卵巢癌治疗中的新兴作用，该领域亟需更有效的靶向疗法。鉴于 ADC 技术的最新进展以及治疗卵巢癌（尤其是晚期和复发病例）所面临的持续挑战，这篇综述既及时又具有现实意义。它综合了当前的研究成果和临床试验数据，强调了 ADC 彻底改变卵巢癌治疗的潜力：本综述涵盖的关键主题包括 ADCs 的作用机制、其靶向卵巢癌细胞的特异性、最新临床试验结果、提高疗效和降低毒性的 ADC 设计进展以及克服卵巢癌耐药性的策略。综述强调了 ADC 对临床实践产生重大影响的潜力，为卵巢癌患者提供了更有效、更个性化的治疗方法。综述提出了这一恶性肿瘤治疗模式的转变，强调了在这一领域进一步研究和开发的必要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Opinion in Obstetrics & Gynecology 医学-妇产科学

CiteScore

4.10

自引率

0.00%

发文量

104

审稿时长

6-12 weeks

期刊介绍： Current Opinion in Obstetrics and Gynecology is a bimonthly publication offering a unique and wide ranging perspective on the key developments in the field. Each issue features hand-picked review articles from our team of expert editors. With eleven disciplines published across the year – including reproductive endocrinology, gynecologic cancer and fertility– every issue also contains annotated references detailing the merits of the most important papers.